mdlinx mdlinx
Oncology Articles on MDLinx

Significance of Uracil/Tegafur for Preventing Intravesical Recurrence of Non-Muscle Invasive Urothelial Carcinoma of the Bladder Current Urology, 05/25/2012

Harada KI et al. – Despite the significant induction of γ–butyrolactone (GBL), adjuvant uracil/tegafur (UFT) therapy failed to show a preventive effect on intravesical recurrence of non–muscle invasive urothelial carcinoma of the bladder. Therefore, the authors should consider enhancing the anti–angiogenic effect of GBL using an alternative administration schedule of UFT.

Read this article on Current Urology



Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close